Skip to main content

PDL BioPharma Value Stock - Dividend - Research Selection

PDL BioPharma

ISIN: US69329Y1047, WKN: A0H1J1

Market price date: 19.03.2021
Market price: 2,47 USD




PDL BioPharma Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-03-2020
Cash flow
Net operating cash flow -32.443.000
Capital Expenditures -2.463.000
Free cash flow -34.906.000
Balance sheet
Total Equity 1.141.000
Liabilities & Shareholders equity 716.119.000
Income statement
Net income -70.411.000
Eps (diluted) -0,590
Diluted shares outstanding 118.631.000
Net sales/revenue 433.000

Fundamental ratios calculated on: 19-03-2021

Ratios
Key figures 19-03-2021
Cash flow
P/C -9,03
   
P/FC -8,40
Balance sheet
ROI-9,83
ROE82,84
Income statement
P/E-4,19
Div. Yield0,00%
P/B0,49
P/S676,72


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolPDLI
Market Capitalization293.018.560,00 USD
Country
Indices
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2001-10-10,2.0000/1.0000; 2000-08-23,2.0000/1.0000
Internetwww.pdl.com


Description of the company

PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.pdl.com